Baseline Characteristics of Patients with Acute DVT or PE
| Characteristic | DVT (n = 10) | PE (n = 10) | Total |
| Demographic | |||
| Age (y) | 59.9 ± 13.8 | 58.4 ± 18.1 | 59.2 ± 15.7 |
| Male sex | 5 (50%) | 4 (40%) | 9 (45%) |
| Non-Hispanic/Latino and Asian (Korean) | 10 (100%) | 10 (100%) | 20 (100%) |
| Clinical feature | |||
| Duration of signs and symptoms (d)* | 18.8 ± 11.4 | 9.5 ± 8.7 | 14.2 ± 11.0 |
| Active cancer | 1 (10%) | 1 (10%) | 2 (10%) |
| Paralysis, paresis, or recent immobilization | 1 (10%) | None | 1 (5%) |
| Recently bedridden > 3 d or major surgery | 3 (30%) | 1 (10%) | 4 (20%) |
| Estrogen use by women | None | 1 (10%) | 1 (5%) |
| Body mass index ≥ 30 kg/m2 | 1 (10%) | 2 (20%) | 3 (15%) |
| Laboratory test (d-dimer [μg/mL FEU]) | 9.7 ± 5.4 | 7.0 ± 4.7 | 8.4 ± 5.1 |
| Treatment before 18F-GP1 PET/CT | |||
| Duration of anticoagulant therapy (d)† | 2.8 ± 1.1 | 3.2 ± 1.1 | 3.0 ± 1.1 |
| Prior antiplatelet therapy | 4 (40%) | 1 (10%) | 5 (25%) |
↵* Duration before 18F-GP1 PET/CT.
↵† Duration of anticoagulation therapy before 18F-GP1 PET/CT or interval between standard imaging studies and 18F-GP1 PET/CT.
FEU = fibrinogen-equivalent units.
Qualitative data are expressed as numbers, followed by percentages in parentheses; continuous data are expressed as mean ± SD.